Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 8,376 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule Clear all
Completed Phase 1 Interventional

Study of the Fecal Microbiome in Patients With Parkinson's Disease

NCT03671785
View directory record Official record
Conditions
Parkinson Disease
Interventions
PRIM-DJ2727, Placebo oral capsule
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
55 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 25, 2026, 4:34 PM EDT
Terminated Phase 2 Interventional Results available

Carvedilol in Treating Hypoglycemia Unawareness

NCT03538015
View directory record Official record
Conditions
Hypoglycemia Unawareness
Interventions
Carvedilol 3.125 mg, Carvedilol 2.5 mg, Placebo capsule
Drug
Lead sponsor
Owen Chan, PhD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 25, 2026, 4:34 PM EDT
Suspended Early Phase 1 Interventional

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

NCT04975217
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Fecal Microbiota Transplantation, Fecal Microbiota Transplantation Capsule, Questionnaire Administration, Resection, Therapeutic Colonoscopy
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 4:34 PM EDT
Recruiting Phase 2 Interventional

A Polypill for Acute Coronary Syndrome

NCT07032389
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Polypill
Combination Product
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 25, 2026, 4:34 PM EDT
Recruiting Phase 4 Interventional

Preoperative Acetazolamide

NCT07101250
View directory record Official record
Conditions
Post Operative Pain, Laparoscopic Hysterectomy, Referred Pain
Interventions
Acetazolamide 500 MG Extended Release Oral Capsule, Placebo
Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 4:34 PM EDT
Active, not recruiting Not applicable Interventional

Monounsaturated Fatty Acid Supplementation for Overweight and Obese Individuals With Prediabetes

NCT05560971
View directory record Official record
Conditions
PreDiabetes, Insulin Resistance, Overweight, Obesity
Interventions
Palmitoleic acid, Placebo
Dietary Supplement · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Phase 2 Interventional

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

NCT00095732
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Liprotamase, Placebo
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
27
States / cities
Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

NCT01380093
View directory record Official record
Conditions
Nondependent Opioid Abuse, Episodic
Interventions
Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Phase 3 Interventional Results available

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

NCT03566238
View directory record Official record
Conditions
PFIC1, PFIC2
Interventions
A4250 (odevixibat), Placebo
Drug
Lead sponsor
Albireo
Industry
Eligibility
6 Months to 18 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 25, 2026, 4:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Cocoa to Maximize Exercise Training in Older Adults - The COMET Trial

NCT07161726
View directory record Official record
Conditions
Mobility Disability
Interventions
(-)-Epicatechin-rich cocoa supplementation combined with exercise training, Placebo combined with exercise training
Combination Product
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Phase 1 Interventional

Evaluate the Effect of Elimune Capsules

NCT02251678
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Elimune Capsules
Dietary Supplement
Lead sponsor
Elorac, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Chicago, Illinois • Lake Forest, Illinois • Fair Lawn, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

NCT04939428
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
59
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 25, 2026, 4:34 PM EDT
Recruiting Not applicable Interventional

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

NCT04513028
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
Beta-Glucan
Dietary Supplement
Lead sponsor
Kelly McMasters
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Phase 1 Interventional

Safety Study of Larazotide Acetate to Treat Celiac Disease.

NCT00386165
View directory record Official record
Conditions
Celiac Disease
Interventions
larazotide acetate
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics

NCT01822665
View directory record Official record
Conditions
Gastrointestinal Mucosal Damage
Interventions
Ibuprofen, Paracetamol, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 25, 2026, 4:34 PM EDT
Terminated Phase 2 Interventional Results available

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

NCT01978236
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
Dabrafenib 150 mg, Trametinib 2.0 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sustiva Levels With Use of a Gel Capsule

NCT01087814
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Efavirenz, Over-encapsulated efavirenz
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Dosage Forms of LY2886721 in Healthy Participants

NCT01775904
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2886721 in a Capsule, LY2886721 in an orally disintegrating tablet (ODT)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 25, 2026, 4:34 PM EDT
Terminated Phase 3 Interventional

Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial

NCT02950233
View directory record Official record
Conditions
Pain, Postoperative
Interventions
NMDA active, Steroid active, NMDA placebo, Steroid placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 25, 2026, 4:34 PM EDT
Recruiting Phase 4 Interventional

Bone, Exercise, Alendronate, and Caloric Restriction

NCT05764733
View directory record Official record
Conditions
Bone Loss
Interventions
Bisphosphonate, Resistance Training/Bone-Loading Exercise, Placebo
Drug · Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture (VITAL)

NCT01747447
View directory record Official record
Conditions
Bone Density, Body Composition, Bone Health
Interventions
Vitamin D3 placebo, Fish oil placebo, omega-3 fatty acids (fish oil), Vitamin D3
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
771 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Phase 2 Interventional

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

NCT00722358
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-650032, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Anaheim, California • Orlando, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 25, 2026, 4:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Eszopiclone on Sleep and Memory in Schizophrenia

NCT01641900
View directory record Official record
Conditions
Schizophrenia
Interventions
eszopiclone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 25, 2026, 4:34 PM EDT